Health Condition 1: N182- Chronic kidney disease, stage 2 (mild) Health Condition 2: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 3: N184- Chronic kidney disease, stage 4 (severe) Health Condition 4: N186- End stage renal disease
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Strand Life Sciences Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Individuals of 18 years or above with confirmed diagnosis of CKD with eGFR less than 90 ml/min and other available clinical parameters (age of onset, method of diagnosis, phenotypic characteristics, any information on repeated occurrence, associated SOC test results) Individuals from the general population of any sex and race Individuals who has the ability to understand and willing to sign the Informed consent form Willingness to contribute 20-23 ml blood
Exclusion criteria
Exclusion criteria: Patients with acute nephrology disorders or disorders pertaining to autoimmune or genetic conditions like lupus nephritis or polycystic kidney disease Patients not consenting or unable to give an informed written consent Patients not meeting the inclusion criteria or judged by the investigator to be unsuitable for inclusion into the study Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of signature biomarkers via a minimally invasive procedure will enable identification of pivotal genetic factors that contribute to the development and progression of different stages of CKD.Timepoint: 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Pvt Ltd
Outcome results
None listed